NASDAQ:HUGE FSD Pharma - HUGE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.45 -0.11 (-7.05%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.39▼$1.5850-Day Range$0.94▼$1.8152-Week Range$0.62▼$1.88Volume81,786 shsAverage Volume171,490 shsMarket Capitalization$55.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About FSD Pharma (NASDAQ:HUGE) StockFSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.Read More Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE Stock News HeadlinesMarch 22, 2023 | marketwatch.comFSD Pharma Gets Green Light for Depression-Drug Clinical Trial in AustraliaMarch 22, 2023 | finance.yahoo.comFSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive DisorderMarch 24, 2023 | Upexi, Inc (Ad)Could This Be The Biggest Stock Of 2023?This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!March 14, 2023 | msn.comPsychedelics Company Conducts Investigation Into Potential Naked Short Selling Of Its StockMarch 14, 2023 | finance.yahoo.comFSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its StockMarch 1, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory BoardFebruary 28, 2023 | benzinga.comShark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics CompanyFebruary 28, 2023 | finance.yahoo.comOriginal "Shark" and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory BoardMarch 24, 2023 | Upexi, Inc (Ad)Could This Be The Biggest Stock Of 2023?This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!February 14, 2023 | finance.yahoo.comFSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol MisuseFebruary 13, 2023 | baystreet.caAllied, FSD, Magnet at 52-Week HighsFebruary 9, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MSFebruary 7, 2023 | finance.yahoo.comFSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug CandidateFebruary 3, 2023 | theglobeandmail.comFSD Pharma breaks out of its trading range after insiders bet on company prospectsJanuary 30, 2023 | proactiveinvestors.comFSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCASJanuary 30, 2023 | wsj.comRecruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)January 19, 2023 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MSJanuary 13, 2023 | proactiveinvestors.comFSD Pharma plans buyback of up to 1.9 million shares to utilize cash reservesJanuary 12, 2023 | morningstar.comFSD Pharma Inc Ordinary Shares - Class B (Sub Voting) HUGE Stock QuoteNovember 29, 2022 | proactiveinvestors.comFSD Pharma announces changes to its board of directorsNovember 28, 2022 | finance.yahoo.comFSD Pharma Announces Changes to the Board of DirectorsNovember 15, 2022 | finance.yahoo.comInvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its EntiretyNovember 10, 2022 | finance.yahoo.comFSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza BokhariOctober 1, 2022 | seekingalpha.comHUGE FSD Pharma Inc.September 12, 2022 | finance.yahoo.comFSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation AvailableSeptember 6, 2022 | proactiveinvestors.comFSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorderJuly 13, 2022 | finance.yahoo.comFSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International SymposiumSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE Company Calendar Today3/23/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HUGE CUSIPN/A CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.50% Return on Assets-50.08% Debt Debt-to-Equity RatioN/A Current Ratio3.41 Quick Ratio3.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book1.08Miscellaneous Outstanding Shares38,100,000Free Float34,854,000Market Cap$55.25 million OptionableOptionable Beta0.61 Key ExecutivesAnthony J. DurkaczExecutive Co-Chairman & Chief Executive OfficerZeeshan SaeedExecutive Co-Chairman & PresidentDonal CarrollChief Operating Officer & DirectorNathan CoyleChief Financial Officer & ControllerSandy HuardHead-Investor Relations & CommunicationsKey CompetitorsGain TherapeuticsNASDAQ:GANXLongeveronNASDAQ:LGVNUnity BiotechnologyNASDAQ:UBXSyros PharmaceuticalsNASDAQ:SYRSAssembly BiosciencesNASDAQ:ASMBView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 31,200 shares on 2/14/2023Ownership: 0.140%Group One Trading L.P.Sold 300 shares on 2/9/2023Ownership: 0.000%View All Institutional Transactions HUGE Stock - Frequently Asked Questions How have HUGE shares performed in 2023? FSD Pharma's stock was trading at $0.7884 on January 1st, 2023. Since then, HUGE shares have increased by 83.9% and is now trading at $1.45. View the best growth stocks for 2023 here. Are investors shorting FSD Pharma? FSD Pharma saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 456,800 shares, an increase of 37.4% from the February 13th total of 332,500 shares. Based on an average daily trading volume, of 149,200 shares, the days-to-cover ratio is presently 3.1 days. Currently, 2.8% of the shares of the stock are sold short. View FSD Pharma's Short Interest. When is FSD Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our HUGE earnings forecast. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other FSD Pharma investors own include Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Assertio (ASRT), Bionano Genomics (BNGO), Ideanomics (IDEX), Stealth BioTherapeutics (MITO), Millendo Therapeutics (MLND), 9 Meters Biopharma (NMTR) and Selecta Biosciences (SELB). What is FSD Pharma's stock symbol? FSD Pharma trades on the NASDAQ under the ticker symbol "HUGE." Who are FSD Pharma's major shareholders? FSD Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of FSD Pharma? Shares of HUGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is FSD Pharma's stock price today? One share of HUGE stock can currently be purchased for approximately $1.45. How much money does FSD Pharma make? FSD Pharma (NASDAQ:HUGE) has a market capitalization of $55.25 million. How can I contact FSD Pharma? FSD Pharma's mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The official website for the company is fsdpharma.com. The company can be reached via phone at (416) 854-8884 or via email at ir@fsdpharma.com. This page (NASDAQ:HUGE) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.